Comparison of insulin intensification strategies with insulin lispro low mixture twice daily versus basal insulin glargine and prandial insulin lispro once daily in East Asian and Caucasian patients with type 2 diabetes mellitus

Jeong, In Kyung; Chung, Choon Hee; Zhou, Zhiguang; Han, Jeong Hee; Duan, Ran; Edralin, Diana M.; Rodríguez, Ángel

doi:10.1111/1753-0407.12426

Cited by 5 publications

(26 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In all of these studies, the change from baseline in HbA1c was, in general, not significantly different between the premixed insulin analog and basal–bolus groups, with one study showing non‐inferiority on the basis of this comparison. Another showed a significantly greater decrease in HbA1c in the premixed insulin analog group compared with the basal–bolus group . Likewise, other outcomes, including the incidence of hypoglycemia and weight/BMI gain, were not significantly different between groups (or favored the premixed insulin analog group), except in the study reported by Hirao et al ,.…”

Section: Resultsmentioning

confidence: 91%

“…Of these #bib165 were duplicates and 356 were excluded. Three additional studies were identified (including two that had been submitted, but not published at the time of the literature search); hence 18 studies from the literature were included in the review. Three eligible studies were identified in the search of ClinicalTrials.gov and included.…”

Section: Resultsmentioning

confidence: 99%

“…Most studies ( n = 14) were carried out in China or Japan; there were four multicountry studies (Table ).…”

Section: Resultsmentioning

confidence: 99%

“…Of the eight studies reporting data, SMBG/SMPG concentrations were generally decreased from baseline for each assessment point during the day after treatment with premixed insulin analogs (Table ; note: SMBG/SMPG results from these studies were typically focused on the comparison between treatment groups [see Table for further details]).…”

Section: Resultsmentioning

confidence: 99%

“…Two studies reported data for East Asian and Caucasian patients. In the study reported by Ji et al ,.…”

Section: Resultsmentioning

confidence: 99%

See 4 more Smart Citations

Efficacy and safety of premixed insulin analogs in Asian patients with type 2 diabetes: A systematic review

Sheu

Lee

et al. 2017

J of Diabetes Invest

Self Cite

View full text Add to dashboard Cite

Aims/IntroductionThe primary aim of this systematic review was to provide an overview of the efficacy and safety of premixed insulin analogs in Asians, specifically East Asians, with type 2 diabetes.Material and MethodsThe MEDLINE, Embase, Cochrane Library and ClinicalTrials.gov databases were searched from 1 January 1995 to 26 November 2015. Randomized controlled trials involving East Asians with type 2 diabetes treated with any premixed insulin analog were included. Major comparator treatments were basal insulin and basal–bolus insulin. Comparisons were also made between East Asian and Caucasian patients. The primary efficacy outcome was glycated hemoglobin change from baseline to end‐point. The primary safety outcome was the incidence of hypoglycemia.ResultsA total of 21 studies were included; most (n = 14) were carried out in China or Japan. The duration of treatment ranged from 12 to 48 weeks. The glycated hemoglobin mean/least squares mean change from baseline to end‐point after treatment with premixed insulin analogs ranged from −0.12 to −4.2% (improvement was generally more pronounced with insulin initiation vs intensification). The incidence of hypoglycemia ranged from 8.3 to 72.0% in most studies, with the variability reflecting the definition of hypoglycemia used. Efficacy and safety outcomes for premixed insulin analogs were generally similar to those for basal or basal–bolus insulin. Limited evidence suggests that dosing, efficacy and safety profiles might differ slightly between East Asian and Caucasians receiving premixed insulin analogs.ConclusionsThese results support the current use of premixed insulin analogs for managing East Asian patients with type 2 diabetes.

show abstract

Section: Resultsmentioning

confidence: 91%

Section: Resultsmentioning

confidence: 99%

“…Most studies ( n = 14) were carried out in China or Japan; there were four multicountry studies (Table ).…”

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

“…Two studies reported data for East Asian and Caucasian patients. In the study reported by Ji et al ,.…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Efficacy and safety of premixed insulin analogs in Asian patients with type 2 diabetes: A systematic review

Sheu

Lee

et al. 2017

J of Diabetes Invest

Self Cite

View full text Add to dashboard Cite

show abstract

A Review of Basal-Bolus Therapy Using Insulin Glargine and Insulin Lispro in the Management of Diabetes Mellitus

2018

View full text Add to dashboard Cite

Basal-bolus therapy (BBT) refers to the combination of a long-acting basal insulin with a rapid-acting insulin at mealtimes. Basal insulin glargine 100 U/mL and prandial insulin lispro have been available for many years and there is a substantial evidence base to support the efficacy and safety of these agents when they are used in BBT or basal-plus therapy for patients with type 1 or type 2 diabetes mellitus (T1DM, T2DM). With the growing availability of alternative insulins for use in such regimens, it seems timely to review the data regarding BBT with insulin glargine 100 U/mL and insulin lispro. In patients with T1DM, BBT with insulin glargine plus insulin lispro provides similar or better glycemic control and leads to less nocturnal hypoglycemia compared to BBT using human insulin as the basal and/or prandial component, and generally provides similar glycemic control and rates of severe hypoglycemia to those achieved with insulin lispro administered by continuous subcutaneous insulin infusion (CSII). Studies evaluating BBT with insulin glargine plus insulin lispro in patients with T2DM also demonstrate the efficacy and safety of these insulins. Available data suggest that BBT with insulin glargine and insulin lispro provides similar levels of efficacy and safety in pediatric and adult populations with T1DM and in adult patients and those aged more than 65 years with T2DM. These insulin preparations also appear to be safe and effective for controlling T2DM in people of different ethnicities and in patients with T1DM or T2DM and comorbidities.FundingEli Lilly and Company.

show abstract

Use of Insulin Glargine 100 U/mL for the Treatment of Type 2 Diabetes Mellitus in East Asians: A Review

et al. 2019

View full text Add to dashboard Cite

Insulin glargine (IGlar) 100 U/mL (IGlar-100) is widely used in East Asian countries for the treatment of type 2 diabetes mellitus (T2DM) and is the gold standard of basal insulin treatment. In this review we summarize key information about clinical experience with IGlar-100 in East Asian patients with T2DM, including findings from clinical trials and postmarketing studies. We also provide recommendations and opinions on the optimal use of IGlar-100 in this population. The findings from the studies highlighted in our review indicate that IGlar-100 can be a suitable treatment option for East Asians with T2DM, from initial therapy in combination with oral antihyperglycemic medications through to different combinations and intensification models. Funding Eli Lilly and Company.

show abstract

Comparison of insulin intensification strategies with insulin lispro low mixture twice daily versus basal insulin glargine and prandial insulin lispro once daily in East Asian and Caucasian patients with type 2 diabetes mellitus

Abstract: Both strategies improved glycemic control in a small group of EA and Caucasian patients not adequately controlled on insulin glargine plus metformin and/or pioglitazone.

Cited by 5 publications

References 23 publications

Efficacy and safety of premixed insulin analogs in Asian patients with type 2 diabetes: A systematic review

Efficacy and safety of premixed insulin analogs in Asian patients with type 2 diabetes: A systematic review

A Review of Basal-Bolus Therapy Using Insulin Glargine and Insulin Lispro in the Management of Diabetes Mellitus

Use of Insulin Glargine 100 U/mL for the Treatment of Type 2 Diabetes Mellitus in East Asians: A Review

Contact Info

Product

Resources

About